title: Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein.
abstract: Overexpression of the xenotoxin transporter P-glycoprotein (P-gp) represents one major reason for the development of multidrug resistance (MDR), leading to the failure of antibiotic and cancer therapies. Inhibitors of P-gp have thus been advocated as promising candidates for overcoming the problem of MDR. However, due to lack of a high-resolution structure the concrete mode of interaction of both substrates and inhibitors is still not known. Therefore, structure-based design studies have to rely on protein homology models. In order to identify binding hypotheses for propafenone-type P-gp inhibitors, five different propafenone derivatives with known structure-activity relationship (SAR) pattern were docked into homology models of the apo and the nucleotide-bound conformation of the transporter. To circumvent the uncertainty of scoring functions, we exhaustively sampled the pose space and analyzed the poses by combining information retrieved from SAR studies with common scaffold clustering. The results suggest propafenone binding at the transmembrane helices 5, 6, 7 and 8 in both models, with the amino acid residue Y307 playing a crucial role. The identified binding site in the non-energized state is overlapping with, but not identical to, known binding areas of cyclic P-gp inhibitors and verapamil. These findings support the idea of several small binding sites forming one large binding cavity. Furthermore, the binding hypotheses for both catalytic states were analyzed and showed only small differences in their protein-ligand interaction fingerprints, which indicates only small movements of the ligand during the catalytic cycle.
authors: Department of Medicinal Chemistry, University of Vienna, Vienna, Austria.
authors: Freya
authors: F
authors: Klepsch
authors: Peter
authors: P
authors: Chiba
authors: Gerhard F
authors: GF
authors: Ecker
references: Biochim Biophys Acta. 2009 May;1794(5):725-37
references: 19135557
references: J Supramol Struct. 1976;4(4):521-6
references: 933538
references: FEBS J. 2009 Feb;276(4):964-72
references: 19215299
references: Biochemistry. 2001 Feb 6;40(5):1413-22
references: 11170469
references: Semin Cell Dev Biol. 2001 Jun;12(3):247-56
references: 11428917
references: Mol Pharm. 2006 Jan-Feb;3(1):3-25
references: 16686365
references: Mol Pharmacol. 2002 Mar;61(3):637-48
references: 11854445
references: J Comput Aided Mol Des. 2004 Jan;18(1):23-40
references: 15143801
references: J Biol Chem. 2008 Feb 29;283(9):5769-79
references: 18093977
references: Mol Pharmacol. 2005 Feb;67(2):365-74
references: 15509712
references: Biochemistry. 2002 Apr 9;41(14):4744-52
references: 11926837
references: Curr Top Med Chem. 2010;10(17):1769-74
references: 20645918
references: Biochem J. 2006 Oct 15;399(2):351-9
references: 16813563
references: Mini Rev Med Chem. 2005 Feb;5(2):153-63
references: 15720285
references: J Biol Chem. 2002 Nov 15;277(46):44332-8
references: 12223492
references: J Biol Chem. 2003 Oct 10;278(41):39706-10
references: 12909621
references: J Mol Biol. 1993 Dec 5;234(3):779-815
references: 8254673
references: Arch Pharm (Weinheim). 2004 Jun;337(6):317-27
references: 15188221
references: FEBS J. 2009 Dec;276(23):7016-26
references: 19878299
references: Nat Rev Cancer. 2005 Apr;5(4):275-84
references: 15803154
references: Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
references: 20057044
references: Nature. 2006 Sep 14;443(7108):180-5
references: 16943773
references: Mol Pharmacol. 2010 Dec;78(6):1026-35
references: 20829432
references: Biochem Biophys Res Commun. 2010 May 7;395(3):436-40
references: 20394729
references: Curr Med Chem. 2006;13(7):793-805
references: 16611068
references: Mol Inform. 2010 Apr 12;29(4):276-86
references: 27463054
references: Mol Pharmacol. 1996 Jun;49(6):1122-30
references: 8649352
references: Proteins. 2003 Sep 1;52(4):609-23
references: 12910460
references: Mol Biol Cell. 1996 Oct;7(10):1485-98
references: 8898356
references: Clin Pharmacol Ther. 2007 Feb;81(2):298-304
references: 17259955
references: FASEB J. 2007 Dec;21(14):3937-48
references: 17627029
references: Biochemistry. 2005 Oct 25;44(42):14020-9
references: 16229491
references: Nucleic Acids Res. 2009 Jul;37(Web Server issue):W510-4
references: 19429685
references: FEBS Lett. 2006 Feb 13;580(4):1056-63
references: 16380120
references: Science. 2009 Mar 27;323(5922):1718-22
references: 19325113
references: Trends Biochem Sci. 2010 Jan;35(1):36-42
references: 19819701
references: Nat Rev Drug Discov. 2010 Apr;9(4):273-6
references: 20357802
references: ChemMedChem. 2008 Feb;3(2):280-95
references: 18175303
references: J Biol Chem. 1997 Dec 19;272(51):31945-8
references: 9405384
references: Mol Pharmacol. 2011 Mar;79(3):443-52
references: 21177413
references: Arch Biochem Biophys. 2008 Aug 1;476(1):51-64
references: 18328253
references: Pflugers Arch. 2007 Feb;453(5):555-67
references: 16937116
references: ChemMedChem. 2009 Nov;4(11):1883-96
references: 19768722
references: Biochemistry. 2007 Dec 4;46(48):13787-99
references: 17988154
references: J Biol Chem. 2007 Nov 2;282(44):32043-52
references: 17848563
references: J Biol Chem. 2002 Nov 1;277(44):41303-6
references: 12226074
references: J Biol Chem. 1998 Jun 12;273(24):14671-4
references: 9614062
references: Nat Rev Drug Discov. 2007 Nov;6(11):881-90
references: 17971784
references: Bioorg Med Chem Lett. 2007 Aug 1;17(15):4258-61
references: 17532632